Syngeneic mouse tumor models investigating the noncyclic dinucleotide small-molecule STING agonist MK-2118 demonstrated that IT, subcutaneous (SC), and oral administration resulted in dose-dependent antitumor activity, with complete tumor regression observed in 80% to 100% of treated animals (7). Here, STING1 is linked to neoplasm.